Galectin Therapeutics Inc (GALT) Stock Analysis

Galectin Therapeutics Inc (GALT) is a publicly traded company in the HEALTHCARE sector. It trades at $2.42, carries a market capitalization of $171.89M. This page summarizes the public market data, fundamentals, and frequently asked questions for GALT, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Galectin Therapeutics Inc currently has a Neutral sentiment score of -0.06.

About Galectin Therapeutics Inc

Galectin Therapeutics Inc. (GALT) is a clinical-stage biopharmaceutical company based in Norcross, Georgia, specializing in the discovery and development of innovative therapies targeting fibrotic diseases, cancer, and other severe medical conditions. The company's proprietary technology focuses on galectin proteins, which play critical roles in disease progression and tissue inflammation, positioning Galectin Therapeutics to address significant unmet medical needs. With a robust pipeline and...

GNG Research Analysis

GNG Research scores Galectin Therapeutics Inc (GALT) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for GALT.

Frequently Asked Questions

Does GALT pay dividends?

Galectin Therapeutics Inc (GALT) does not currently pay a regular dividend.

What is GALT's market cap?

Galectin Therapeutics Inc (GALT) has a market capitalization of $171.89M with a current stock price of $2.42.